AP3
DEAD

Serial Number

98851818

Owner

Acrivon Therapeutics, Inc.

Attorney

Sara M. Bauer

Filing Date

Nov 13, 2024

Add to watchlist:

No watchlists yet
View on USPTO

AP3 Trademark

Serial Number: 98851818

AP3 is a trademark filed by Acrivon Therapeutics, Inc. on November 13, 2024. The trademark is classified under Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Acrivon Therapeutics, Inc. (6 trademarks)

480 Arsenal Way, Suite 100
Watertown, MA 02472

Entity Type: 03

Trademark Details

Filing Date

November 13, 2024

Registration Date

Not Registered

Goods & Services

Medical services; medical testing for diagnosis or treatment purposes; medical diagnostic testing, monitoring, and reporting services; providing medical information, consultancy and advisory services; individual medical counseling services provided to patients; providing a website featuring information in the field of precision medicine; providing medical information to medical professionals in the form of reports in the field of precision medicine; proteomics and biomarker discovery services, namely, medical diagnostic services

scientific research; medical research; proteomics and biomarker discovery services, namely, medical testing services and information in the field of disease classification; scientific research and development in the fields of pharmaceuticals, therapeutics, and drug formulation and delivery; scientific research and development in the fields of proteomics and biomarker discovery; consultancy services in the field of pharmaceutical research and development services; consultancy services in the fields of medical and scientific research concerning proteomics and biomarker discovery; pharmaceutical research services related to prediction of drug treatment efficacy; medical research services related to prediction of drug treatment efficacy; conducting scientific studies in the fields of proteomics, biomarker discovery, rational drug design in drug discovery, patient responder identification and indication finding, precision medicine clinical trials based on responder identification; proteomics, biomarker discovery, rational drug design in drug discovery, patient responder identification and indication finding, precision medicine clinical trials based on responder identification; providing information in the field of medical, scientific and pharmaceutical research about proteomics, biomarker discovery, rational drug design in drug discovery, patient responder identification and indication finding, precision medicine clinical trials based on responder indication services; scientific and technological research and consultation services, namely, in the medical, pharmaceutical, and scientific research fields of drug-tailored, efficacy-predictive biomarkers, pharmacodynamic biomarkers, drug repurposing, patient responder identification, indication finding, and rational drug design; drug discovery services in the medical, pharmaceutical, and scientific research fields of drug-tailored, efficacy-predictive biomarkers, patient responder identification, pharmacodynamic biomarkers, drug repurposing, and rational drug design through optimal pathway effects in intact cells; consultancy in the field of pharmaceutical research and development services in the medical, pharmaceutical, and scientific research fields of drug-tailored, efficacy-predictive biomarkers, patient responder identification, pharmacodynamic biomarkers, drug repurposing, indication finding, and rational drug design through pathway-based SAR

Filing History

ABANDONMENT NOTICE E-MAILED - EXPRESS ABANDONMENT
Mar 25, 2026 MAB1
ABANDONMENT - EXPRESS MAILED
Mar 25, 2026 ABN1
TEAS EXPRESS ABANDONMENT RECEIVED
Mar 24, 2026 EXAR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 6, 2026 GNRN
NON-FINAL ACTION E-MAILED
Feb 6, 2026 GNRT
NON-FINAL ACTION WRITTEN
Feb 6, 2026 CNRT
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Aug 28, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Aug 28, 2025 GNSL
SUSPENSION LETTER WRITTEN
Aug 28, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 7, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 7, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 7, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 9, 2025 GNRN
NON-FINAL ACTION E-MAILED
Jun 9, 2025 GNRT
NON-FINAL ACTION WRITTEN
Jun 9, 2025 CNRT
LETTER OF PROTEST EVIDENCE REVIEWED - ACTION TAKEN
Jun 9, 2025 LOPE
LETTER OF PROTEST EVIDENCE FORWARDED
Jun 8, 2025 LOPT
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 9, 2025 GNRN
NON-FINAL ACTION E-MAILED
May 9, 2025 GNRT
NON-FINAL ACTION WRITTEN
May 9, 2025 CNRT
ASSIGNED TO EXAMINER
May 9, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 6, 2025 NWOS
NEW APPLICATION ENTERED
Nov 13, 2024 NWAP